Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE versus ROBIMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE versus ROBIMYCIN.
ATROPINE vs ROBIMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists. Inhibits vagal activity, increases heart rate, reduces secretions, and relaxes smooth muscle.
Aminoglycoside antibiotic; binds to 30S ribosomal subunit inhibiting protein synthesis and causing mRNA misreading.
0.5-1 mg IV/IM/SC every 3-5 minutes as needed, up to a total of 3 mg (adults). For preoperative use, 0.4-0.6 mg IM/IV 30-60 minutes before anesthesia.
2.5-5 mg/kg IV every 6 hours; not to exceed 4 g/day.
None Documented
None Documented
2-4 hours (terminal); prolonged in elderly and neonates; clinically requires dosing every 4-6 hours
Clinical Note
moderateBenzatropine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Dronedarone
Terminal elimination half-life 1.5-2.5 hours (prolonged to 3-5 hours in renal impairment; no dose adjustment for mild-moderate impairment but caution in severe).
Renal (30-50% unchanged; remainder as inactive metabolites via hydrolysis and glucuronidation); 50-70% of a dose renally excreted as metabolites; <5% fecal
Renal (urine) 75-85% as unchanged drug; biliary/fecal 10-15%; minor metabolism.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent
"The metabolism of Dronedarone can be decreased when combined with Benzatropine."